

at least sub 21

immunoglobulin having binding specificity to a predetermined ligand, wherein said polypeptide chains are prepared by expression [translation] of a DNA sequence coding for the variable region, said expression occurring in the absence of expression of a DNA sequence coding for natively associated [free of the] constant region, and wherein said two polypeptide chains combine to form the rFv which has a high affinity and specificity for said predetermined ligand.

~~Claim 22, line 4, please delete "to define a domain".~~

REMARKS

In the Office Action, all of the pending claims, Claims 20-25, were rejected on both formal and informal grounds. All of the claims were rejected under 35 U.S.C. 101 as being inoperative and lacking utility. The claims, as well as the specification, were also rejected under 35 U.S.C. 112, first and second paragraphs, as being indefinite for failing to provide an enabling disclosure and for not distinctly claiming the subject matter of the present invention. Further, all of the claims were rejected under 35 U.S.C. 102(b) as being anticipated by or indistinguishable from a series of references. Similarly, the claims were rejected under 35 U.S.C. 103 as being unpatentable over additional references. In view of the above amendments and the following remarks, the Examiner is respectfully requested to withdraw these rejections, and allow Claims 20-25, all of which are considered to be in proper form for allowance.